NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Clinical trial NCT03164603 · COMPLETED
Trial details
- NCT number
- NCT03164603
- Sponsor
- NewLink Genetics Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-29
- Primary completion
- 2019-04-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.